La UCSD estuvo entre los centros que participaron en el estudio de fase dos, ahora en New England Journal of Medicine ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Roche Holding AG (RHHVF – Research Report) and ...

Akeso Inc. scored U.S. FDA approval of the PD-1 monoclonal antibody penpulimab in combination with cisplatin or carboplatin and gemcitabine for the first-line treatment of adult recurrent or ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Qiagen ( QGEN – Research Report) and Viking Therapeutics ( VKTX – Research Report ). Discover outperforming stocks and ...

Analysts fell to the sidelines weighing in on Biogen (BIIB – Research Report) and Sanofi (SNY – Research Report) with neutral ratings, indicating that the experts are neither ...

People with high blood pressure that is uncontrolled or poorly treated with most medications may benefit from a new drug that ...

Mineralys Therapeutics, Inc.’s MLYS share price has dipped by 6.67%, which has investors questioning if this is right time to ...

BioWorld tracked 197 updates across phase I to phase III trials, an increase from 148 in February and 171 in January. The month included 25 positive phase III trial results, while three studies ended ...

Researchers at the University of California San Diego School of Medicine have identified a potential new treatment, an ...

Nerve Recovery Max contains a full spectrum of B Vitamins including B1 (Benfotiamine), B2, B6, B12, Folate, Biotin, and ...

Mineralys Therapeutics (MLYS) announced that the New England Journal of Medicine, or NEJM, published results from the company’s pivotal Phase 2 ...

Significant blood pressure reductions among patients with uncontrolled or resistant hypertension treated with lorundrostat reinforce key role of dysregulated aldosterone in disease onset and ...